What question did this study set out to answer?

To evaluate persistence and adherence rates among patients newly initiated on common classes of antihypertensive medications.

February 1, 2008The Medical Journal of Australia

Persistence with antihypertensive medication: Australia‐wide experience, 2004–2006

View Full Paper

Ask AI

Bookmark

Population

48,690 Australian long-term health concession card holders who had been commenced on an angiotensin II…

Design

Cohort

Follow-up

33 months

Authors

LSLeon A. SimonsGeneral / Preventive / Lipids MOMichael OrtizUniversity of British Columbia GCGordon CalcinoIP Australia

Discussion

Member takes

Implication

Non-persistence with new antihypertensives, especially CCBs, may limit preventive gains; leaves open targeted adherence strategies for testing in trials.

Key Points

To evaluate persistence and adherence rates among patients newly initiated on common classes of antihypertensive medications.
Longitudinal cohort analysis of Pharmaceutical Benefit Scheme claim records between January 2004 and December 2006 in Australia.
Assessed a 10% random sample (N=48,690) of long-term health concession card holders newly started on an A2RA, ACEI, or CCB after at least 6 months with no dispensed antihypertensive therapy.
Across all classes, 19% of patients failed to collect a second prescription, and the overall median persistence duration was 20 months.
Persistence was 57% lower for CCBs compared to the population average (log-rank P < 0.001), with 28% failing to collect a second prescription and a median persistence time of 7 months.
Patients who continued therapy maintained high adherence (median medication possession ratio ~100%), with the highest persistence observed for candesartan, telmisartan, perindopril, and lercanidipine.

Structured PICO

Population

48,690 Australian long-term health concession card holders who had been commenced on an angiotensin II receptor antagonist (A2RA), an angiotensin-converting enzyme inhibitor (ACEI) and/or a calcium channel blocker (CCB), but for whom no antihypertensive medication had been dispensed in the previous 6 months.

Intervention

Initiation of common antihypertensive medications (A2RA, ACEI, and/or CCB)

Outcome

Proportion of patients failing to fill a second prescription; median persistence time with medication

There is significant non-persistence with newly initiated antihypertensive medications, particularly calcium channel blockers, highlighting a missed opportunity for cardiovascular disease prevention.

Cite This Study

Simons et al. (2008) studied this question.

synapsesocial.com/papers/6a70a2b3e5469ee92be157dc https://doi.org/10.5694/j.1326-5377.2008.tb01589.x

Topics

Hypertension management

View Full Paper

Ask AI

Bookmark

Implication

Non-persistence with new antihypertensives, especially CCBs, may limit preventive gains; leaves open targeted adherence strategies for testing in trials.

Persistence with antihypertensive medication: Australia‐wide experience, 2004–2006

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

Topics

Persistence with antihypertensive medication: Australia‐wide experience, 2004–2006

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

Also Consider

Topics

Also Consider